MDC is developing new ways to characterise the physical properties of nanoparticles using single molecule localisation microscopy.
This paper demonstrates the combined in vitro capabilities of Seda Pharmaceutical Development Services in the manufacture and physical characterisation of lipid-based nanoparticles for nucleic acid delivery, coupled with the advanced in vitro characterisation capabilities of Medicines Discovery Catapult (MDC). Together, these organisations can support the design, prototype manufacture and screening of complex medicines ready for progression to preclinical in vivo testing and onwards to clinical development.
Annual Report and Consolidated Financial Statement For the Year Ended 31 March 2024
